Mutual of America Capital Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,432 shares of the biopharmaceutical company’s stock after buying an additional 867 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $21,115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also bought and sold shares of GILD. Buckingham Asset Management LLC increased its position in Gilead Sciences by 2.3% during the 1st quarter. Buckingham Asset Management LLC now owns 5,911 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 131 shares in the last quarter. Baldwin Brothers Inc. MA boosted its stake in Gilead Sciences by 63.3% during the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares during the last quarter. Institute for Wealth Management LLC. boosted its stake in Gilead Sciences by 1.3% during the 4th quarter. Institute for Wealth Management LLC. now owns 11,104 shares of the biopharmaceutical company’s stock valued at $722,000 after purchasing an additional 145 shares during the last quarter. Wright Investors Service Inc. boosted its stake in Gilead Sciences by 0.7% during the 1st quarter. Wright Investors Service Inc. now owns 21,631 shares of the biopharmaceutical company’s stock valued at $1,617,000 after purchasing an additional 147 shares during the last quarter. Finally, Gemmer Asset Management LLC boosted its stake in Gilead Sciences by 17.4% during the 1st quarter. Gemmer Asset Management LLC now owns 992 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 147 shares during the last quarter. Institutional investors and hedge funds own 77.34% of the company’s stock.

In other Gilead Sciences news, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $77.97, for a total transaction of $188,141.61. Following the sale, the director now directly owns 57,273 shares of the company’s stock, valued at $4,465,575.81. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Diane E. Wilfong sold 12,264 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $80.09, for a total value of $982,223.76. Following the sale, the chief accounting officer now directly owns 23,685 shares in the company, valued at $1,896,931.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,585 shares of company stock worth $4,671,283. Insiders own 0.13% of the company’s stock.

Gilead Sciences stock traded down $0.16 during trading on Friday, reaching $73.34. The company had a trading volume of 6,157,451 shares, compared to its average volume of 19,139,120. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97. The firm’s 50-day simple moving average is $77.78 and its 200 day simple moving average is $70.16. The firm has a market capitalization of $92.20 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 3.14 and a beta of 0.72. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.57 by $0.11. The company had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. Gilead Sciences’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $1.67 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 6.34 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Friday, June 12th will be issued a dividend of $0.68 per share. The ex-dividend date is Thursday, June 11th. This represents a $2.72 dividend on an annualized basis and a yield of 3.71%. Gilead Sciences’s dividend payout ratio is presently 44.30%.

Several analysts have commented on GILD shares. Credit Suisse Group reiterated a “sell” rating and set a $60.00 target price on shares of Gilead Sciences in a research note on Friday, April 17th. Bank of America increased their target price on Gilead Sciences from $70.00 to $72.00 and gave the company a “neutral” rating in a research note on Wednesday, February 5th. TheStreet upgraded Gilead Sciences from a “c” rating to a “b-” rating in a research note on Friday, February 21st. Cfra increased their target price on Gilead Sciences from $71.00 to $74.00 and gave the company a “sell” rating in a research note on Wednesday, April 29th. Finally, Mizuho reiterated a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Wednesday, May 13th. Seven analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $78.15.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: The limitations of an equal weight rating

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.